查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016456

全身性紅斑性狼瘡治療市場：按藥物類別、給藥途徑和地區分類，2026-2034 年

Systemic Lupus Erythematosus Drugs Market by Drug Class (Antimalarials Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic and Immunosuppressive Drugs, Biologics, and Others), Mode of Delivery, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球全身性紅斑性狼瘡（SLE）治療市場規模達30億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到48億美元，2026年至2034年的複合年成長率（CAGR）為5.32%。 SLE患者數量的增加、宣傳宣傳活動的活性化以及學名藥的上市是推動市場成長的主要因素。

全身性紅斑性狼瘡（SLE）是一種自體免疫疾病，其特徵是臨床症狀多樣、多重器官發炎（MIS）和復發緩解症候群（RRMS）。它會影響身體的多個部位，包括皮膚、關節、腎臟和大腦。 SLE通常由多種遺傳、環境和荷爾蒙因素引起。症狀包括疲勞、關節疼痛和腫脹、頭痛、皮疹、脫髮、貧血、凝血障礙和發熱。 SLE的診斷主要依據醫護人員的症狀評估、身體檢查、胸部X光片、尿液檢查和血液檢查。抗發炎藥物可用於緩解關節疼痛和僵硬，類固醇乳膏可用於治療皮疹，皮質類固醇可用於抑制免疫反應，抗瘧疾藥可用於治療皮膚問題。對於病情更嚴重的患者，也可以使用緩解疾病藥物和免疫標靶藥物。此外，治療還包括使用各種免疫抑制劑來抑制免疫系統的活性。

全身性紅斑性狼瘡（SLE）治療市場趨勢：

自體自體免疫疾病盛行率的不斷上升以及系統性紅斑狼瘡（SLE）患者數量的持續成長，是全球對SLE治療藥物需求的主要促進因素。此外，許多研究和診斷機構正積極進行宣傳活動，提高大眾對SLE及其治療方法的認知。同時，許多政府和非政府組織（NGO）也正在投資各類項目，旨在開發SLE新治療方法並尋找相關藥物標靶。此外，全球醫療基礎設施和診斷技術投入的增加也促進了市場成長。另外，透過實體藥局和線上零售管道，各種用於緩解SLE相關疼痛、發炎和僵硬症狀的學名藥的便捷獲取，也推動了市場成長。這通常包括非處方藥（OTC）和處方箋Voltaren固醇抗發炎藥（NSAIDs），例如阿斯匹靈、Ibuprofen（Motrin ）、萘普生、雙氯芬酸鈉（ Celebrex ）、非類固醇消炎劑（ Drovid）和吡羅昔康（Felden）。此外，羥氯喹製劑使用量的增加也促進了市場成長。而且，大眾和醫療專業人員對早期診斷和治療系統性紅斑狼瘡（SLE）益處的認知不斷提高，也影響了SLE治療藥物的整體銷售。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全身性紅斑性狼瘡治療的全球市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類別分類

  • 抗瘧疾藥
    • 主要部分
      • Chloroquine
      • 羥氯喹
  • 非類固醇消炎劑（NSAIDs）
  • 細胞毒性藥物和免疫抑制劑
    • 主要部分
      • Cyclophosphamide
      • 胺基甲基葉酸
      • Mycophenolate Mofetil
      • Tacrolimus
      • Cyclosporine
  • 生物製藥
  • 其他

第7章 市場區隔：依給藥途徑

  • 靜脈注射
  • 皮下
  • 口服

第8章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第9章：促進、抑制與機遇

第10章：價值鏈分析

第11章：波特五力分析

第12章：價格分析

第13章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • AstraZeneca Plc
    • Aurinia Pharmaceuticals Inc.
    • GSK plc
    • ImmuPharma Plc
Product Code: SR112026A6799

The global systemic lupus erythematosus (SLE) drugs market size reached USD 3.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 4.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.32% during 2026-2034. The increasing number of patients suffering from SLE, rising public awareness campaigns, and the easy availability of generic drugs represent some of the key factors driving the market.

Systemic lupus erythematosus (SLE) is an autoimmune medical condition characterized by protean clinical manifestations, multisystem inflammation (MIS), and a relapsing and remitting course (RRMS). It affects numerous parts of the body, including the skin, joints, kidneys, and brain. It is generally caused due to various genetic, environmental, and hormonal factors. Its symptoms include fatigue, joint pain and swelling, headache, rashes, hair loss, anemia, blood clotting, and fever. SLE is diagnosed by a healthcare provider using symptom assessments, physical examinations, chest X-rays, urinalysis, and blood tests. Its symptoms can be eased using anti-inflammatory drugs for joint pain and stiffness, steroid creams for rashes, corticosteroids to minimize the immune response, and antimalarial drugs for skin problems. It also uses disease-modifying drugs and targeted immune system agents for more severe cases. Besides this, it is treated using various immunosuppressive drugs that inhibit the activity of the immune system.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET TRENDS:

The increasing prevalence of autoimmune diseases among individuals and the rising number of patients suffering from SLE represents one of the major factors driving the demand for SLE drugs around the world. Moreover, the rising number of research and diagnostics institutes are undertaking measures and introducing public awareness campaigns to educate individuals about SLE and its possible treatments. In addition, governments and non-governmental organizations (NGOs) of numerous countries are investing in various programs to develop novel therapeutics and identify relevant drug targets for the treatment of SLE. This, coupled with the increasing financing to improve healthcare infrastructure and diagnostic technologies worldwide, is impelling the market growth. Apart from this, the easy availability of various generic drugs for relieving pain, inflammation, and stiffness associated with SLE through offline and online retail channels is favoring the market growth. They generally involve over the counter (OTC) and prescription-based nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen (Motrin), naproxen, celecoxib (Celebrex), diclofenac (Voltaren), diflunisal (Dolobid), and piroxicam (Feldene). Furthermore, the increasing use of Hydroxychloroquine drugs is contributing to the market growth. Besides this, the growing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of SLE is influencing the overall sales of SLE drugs.

KEY MARKET SEGMENTATION:

Drug Class Insights:

  • Antimalarials Drugs
    • Chloroquine
    • Hydroxychloroquine
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Cytotoxic and Immunosuppressive Drugs
    • Cyclophosphamide
    • Methotrexate
    • Mycophenolate Mofetil
    • Tacrolimus
    • Cyclosporine
  • Biologics
  • Others

The report has also provided a detailed breakup and analysis of the systemic lupus erythematosus (SLE) drugs market based on the drug class. This includes antimalarials drugs (chloroquine and hydroxycholroquine), non-steroidal anti-inflammatory drugs (NSAIDS), cytotoxic and immunosuppressive drugs (cyclophophamide, methotrexate, mycophenolate mofetil, tacrolimus, and cyclosporine), biologics, and others. According to the report, cytotoxic and immunosuppressive drugs represented the largest segment.

Mode of Delivery Insights:

  • Intravenous
  • Subcutaneous
  • Oral

Regional Insights:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for systemic lupus erythematosus (SLE) drugs. Some of the factors driving the North America systemic lupus erythematosus (SLE) drugs market included easy access to healthcare, the rising awareness about the benefits of early diagnosis and treatment of SLE, and the easy availability of various generic drugs.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global systemic lupus erythematosus (SLE) drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca Plc, Aurinia Pharmaceuticals Inc., GSK plc, and ImmuPharma Plc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the global Systemic Lupus Erythematosus (SLE) drugs market?

2. What is the expected growth rate of the global Systemic Lupus Erythematosus (SLE) drugs market during 2026-2034?

3. What are the key factors driving the global Systemic Lupus Erythematosus (SLE) drugs market?

4. What has been the impact of COVID-19 on the global Systemic Lupus Erythematosus (SLE) drugs market?

5. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the drug class?

6. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the mode of delivery?

7. What are the key regions in the global Systemic Lupus Erythematosus (SLE) drugs market?

8. Who are the key players/companies in the global Systemic Lupus Erythematosus (SLE) drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Systemic Lupus Erythematosus (SLE) Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Antimalarials Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Chloroquine
      • 6.1.2.2 Hydroxychloroquine
    • 6.1.3 Market Forecast
  • 6.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cytotoxic and Immunosuppressive Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Cyclophosphamide
      • 6.3.2.2 Methotrexate
      • 6.3.2.3 Mycophenolate Mofetil
      • 6.3.2.4 Tacrolimus
      • 6.3.2.5 Cyclosporine
    • 6.3.3 Market Forecast
  • 6.4 Biologics
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Mode of Delivery

  • 7.1 Intravenous
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Subcutaneous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 Drivers, Restraints, and Opportunities

  • 9.1 Overview
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Opportunities

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AstraZeneca Plc
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Aurinia Pharmaceuticals Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 GSK plc
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 ImmuPharma Plc
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Systemic Lupus Erythematosus Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Drug Class (in %), 2025
  • Figure 5: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Mode of Delivery (in %), 2025
  • Figure 6: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Systemic Lupus Erythematosus Drugs (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Systemic Lupus Erythematosus Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: North America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: North America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: United States: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: United States: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Canada: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Canada: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: China: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: China: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Japan: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Japan: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: India: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: India: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: South Korea: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: South Korea: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Australia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Australia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Indonesia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Indonesia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Europe: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Europe: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Germany: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Germany: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: France: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: France: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: United Kingdom: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: United Kingdom: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Italy: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Italy: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Spain: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Spain: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Russia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Russia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Latin America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Latin America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Brazil: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Brazil: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Mexico: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Mexico: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Breakup by Country (in %), 2025
  • Figure 71: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Global: Systemic Lupus Erythematosus Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 73: Global: Systemic Lupus Erythematosus Drugs Industry: Value Chain Analysis
  • Figure 74: Global: Systemic Lupus Erythematosus Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Systemic Lupus Erythematosus Drugs Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Mode of Delivery (in Million USD), 2026-2034
  • Table 4: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 5: Global: Systemic Lupus Erythematosus Drugs Market: Competitive Structure
  • Table 6: Global: Systemic Lupus Erythematosus Drugs Market: Key Players